Regulatory
NAD recommends Goli modify, discontinue claims connected to its Ashwagandha Gummies
June 1st 2022The National Advertising Division of BBB National Programs recommended Goli discontinue claims regarding sexual function, weight loss and management, and physical performance after reviewing Goli’s evidence and determining that much of it was not sufficient to support its claims.
AHPA submits comments on mandatory product listing language in FDASLA
May 25th 2022While affirming opposition to mandatory product listing, the American Herbal Products Association offered its feedback and suggested revisions to the discussion draft of the FDA Safety and Landmark Advancements (FDASLA) Act published by the U.S. Senate Committee on Health, Education, Labor, and Pensions (HELP).
EFSA offers positive opinion for use of Bimuno GOS in food for special medical purposes
May 16th 2022Clasado Biosciences has announced that the European Food Safety Authority (EFSA) has given a positive opinion on the extension of the use of galactooligosaccharides (GOS) as a novel food in food for special medical purposes (‘FSMP’) in the EU.
Can a monograph system improve quality and trust in the nutritional supplements market?
April 29th 2022The pandemic saw an influx of opportunities and challenges for dietary supplements, including the emergence of more bad actors in the market. A CBD executive discusses one way the industry can continue to maintain quality and consumer trust: a monograph system.